Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）
Nanjing First Hospital, Nanjing Medical University
180 participants
May 23, 2022
INTERVENTIONAL
Conditions
Summary
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
Eligibility
Inclusion Criteria6
- Age ≥18 years
- Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment
- low density lipoprotein cholesterol \> 70mg/dl (1.8mmol/L)
- Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained.
- Lipid-lowering indications of statins
- Signed an approved informed consents
Exclusion Criteria7
- Contraindications to statins
- There are contraindications to MRI examination or cannot accept MRI examination
- Stenosis caused by vasculitis, arterial dissection and moyamoya disease
- Patients with active bleeding or obvious bleeding tendency
- Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating
- Uncontrolled severe diabetes and hypertension
- Other conditions inappropriate for inclusion judged by investigators
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05397405